+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Genomic Health Inc (GHDX) - Product Pipeline Analysis, 2019 Update

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Agendia Inc
  • bioTheranostics Inc
  • Exact Sciences Corp
  • Grail Inc
  • Hologic Inc
  • Metamark Genetics Inc
  • MORE
Summary

Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Genomic Health Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Agendia Inc
  • bioTheranostics Inc
  • Exact Sciences Corp
  • Grail Inc
  • Hologic Inc
  • Metamark Genetics Inc
  • MORE
Genomic Health Inc Company Overview
  • Genomic Health Inc Company Snapshot
  • Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Genomic Health Inc – Pipeline Analysis Overview
  • Business Description
  • Genomic Health Inc - Key Facts
  • Genomic Health Inc - Major Products and Services
  • Genomic Health Inc Pipeline Products by Development Stage
  • Genomic Health Inc Ongoing Clinical Trials by Trial Status
  • Genomic Health Inc Pipeline Products Overview
  • Diagnostic Test - Non Small Cell Lung Cancer
  • Diagnostic Test - Non Small Cell Lung Cancer Product Overview
  • Liquid Biopsy-Based Bladder Cancer Test
  • Liquid Biopsy-Based Bladder Cancer Test Product Overview
  • Negative Biopsy Test - Prostate Cancer
  • Negative Biopsy Test - Prostate Cancer Product Overview
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay Product Overview
  • Oncotype Dx - Kidney Cancer
  • Oncotype Dx - Kidney Cancer Product Overview
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin Product Overview
  • Oncotype DX IVD Test
  • Oncotype DX IVD Test Product Overview
  • Oncotype DX IVD Test Clinical Trial
  • Oncotype SEQ - Tissue Mutation Panel
  • Oncotype SEQ - Tissue Mutation Panel Product Overview
  • Oncotype TRACK
  • Oncotype TRACK Product Overview
  • Prognostic Test - Melanoma
  • Prognostic Test - Melanoma Product Overview
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma Product Overview
  • Genomic Health Inc - Key Competitors
  • Genomic Health Inc - Key Employees
  • Genomic Health Inc - Key Employee Biographies
  • Genomic Health Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Genomic Health Inc, Recent Developments
  • Jun 04, 2019: Secondary analysis of landmark TAILORx results, published in The New England Journal of Medicine, affirms unique ability of Oncotype DX Breast Recurrence Score Test to predict chemotherapy benefit, guiding adjuvant therapy with even greater precision
  • Jun 03, 2019: Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score Test in node-negative Breast Cancer
  • May 07, 2019: Genomic Health announces first quarter 2019 financial results
  • Mar 25, 2019: New long-term outcomes data presented at St. Gallen International Breast Cancer Conference reinforce TAILORx treatment paradigm and standard of care use for Oncotype DX Breast Recurrence Score test
  • Feb 20, 2019: Genomic Health reports record 2018 fourth quarter and year-end financial results and provides 2019 financial guidance
  • Feb 05, 2019: Oncotype DX Genomic Prostate Score established as first genomic test with prospective validation for predicting adverse pathology in newly diagnosed patients
  • Jan 23, 2019: Gene-expression profiling raises costs for cancer care without improving outcomes for low-risk breast cancer patients, according to researchers
  • Jan 14, 2019: NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer
  • Jan 07, 2019: Genomic Health marks more than 1 million patients worldwide who have benefited from Oncotype DX testing in personalizing cancer treatment decisions to improve outcomes
  • Dec 19, 2018: NICE Expands recommendation for the Oncotype DX Breast Recurrence Score Test to more patients with early-stage breast cancer within the United Kingdom
Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Genomic Health Inc Pipeline Products by Equipment Type
  • Genomic Health Inc Pipeline Products by Indication
  • Genomic Health Inc Ongoing Clinical Trials by Trial Status
  • Genomic Health Inc, Key Facts
  • Genomic Health Inc, Major Products and Services
  • Genomic Health Inc Number of Pipeline Products by Development Stage
  • Genomic Health Inc Pipeline Products Summary by Development Stage
  • Genomic Health Inc Ongoing Clinical Trials by Trial Status
  • Genomic Health Inc Ongoing Clinical Trials Summary
  • Diagnostic Test - Non Small Cell Lung Cancer - Product Status
  • Diagnostic Test - Non Small Cell Lung Cancer - Product Description
  • Liquid Biopsy-Based Bladder Cancer Test - Product Status
  • Liquid Biopsy-Based Bladder Cancer Test - Product Description
  • Negative Biopsy Test - Prostate Cancer - Product Status
  • Negative Biopsy Test - Prostate Cancer - Product Description
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Status
  • Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Description
  • Oncotype Dx - Kidney Cancer - Product Status
  • Oncotype Dx - Kidney Cancer - Product Description
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin - Product Status
  • Oncotype Dx Colon Cancer Assay - Oxaliplatin - Product Description
  • Oncotype DX IVD Test - Product Status
  • Oncotype DX IVD Test - Product Description
  • Oncotype DX IVD Test - An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-receptor Positive/HER2-Negative Primary Breast Cancer
  • Oncotype SEQ - Tissue Mutation Panel - Product Status
  • Oncotype SEQ - Tissue Mutation Panel - Product Description
  • Oncotype TRACK - Product Status
  • Oncotype TRACK - Product Description
  • Prognostic Test - Melanoma - Product Status
  • Prognostic Test - Melanoma - Product Description
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Status
  • Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Description
  • Genomic Health Inc, Key Employees
  • Genomic Health Inc, Key Employee Biographies
  • Genomic Health Inc, Other Locations
  • Genomic Health Inc, Subsidiaries
  • Glossary
List of Figures
  • Genomic Health Inc Pipeline Products by Equipment Type
  • Genomic Health Inc Pipeline Products by Development Stage
  • Genomic Health Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 3
  • Siemens AG
  • NeoGenomics Inc
  • Natera Inc
  • Roche Diagnostics International Ltd
  • Qiagen NV
  • Exact Sciences Corp
  • Personal Genome Diagnostics Inc
  • NanoString Technologies Inc
  • GenomeDx Biosciences Inc
  • Hologic Inc
  • MDxHealth SA
  • Agendia Inc
  • OPKO Health Inc
  • Myriad Genetics Inc
  • Grail Inc
  • Metamark Genetics Inc
  • bioTheranostics Inc
  • Guardant Health Inc
  • Danaher Corp
  • Bio Techne Corp
Note: Product cover images may vary from those shown
Adroll
adroll